Timur Dogan - Cardio Diagnostics Chief Officer
| CDIOW Stock | USD 0.11 0.01 10.00% |
Executive
Timur Dogan is Chief Officer of Cardio Diagnostics Holdings
| Age | 36 |
| Address | 311 West Superior Street, Chicago, IL, United States, 60654 |
| Phone | 302 281 2147 |
| Web | https://cardiodiagnosticsinc.com |
Timur Dogan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Timur Dogan against Cardio Diagnostics stock is an integral part of due diligence when investing in Cardio Diagnostics. Timur Dogan insider activity provides valuable insight into whether Cardio Diagnostics is net buyers or sellers over its current business cycle. Note, Cardio Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cardio Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Timur Dogan over three months ago Acquisition by Timur Dogan of 156750 shares of Cardio Diagnostics at 1.26 subject to Rule 16b-3 | ||
Timur Dogan over a year ago Acquisition by Timur Dogan of 156750 shares of Cardio Diagnostics subject to Rule 16b-3 |
Cardio Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.9795) % which means that it has lost $0.9795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.9327) %, meaning that it generated substantial loss on money invested by shareholders. Cardio Diagnostics' management efficiency ratios could be used to measure how well Cardio Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.24 in 2024. Return On Capital Employed is likely to drop to -2.1 in 2024. At this time, Cardio Diagnostics' Non Current Assets Total are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.12 in 2024, whereas Other Current Assets are likely to drop slightly above 974.7 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ingmar MD | Zentalis Pharmaceuticals Llc | 49 | |
| Scott MD | Protagonist Therapeutics | N/A | |
| David Liu | Protagonist Therapeutics | 74 | |
| Steve Sabus | Syndax Pharmaceuticals | 57 | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Hequn Yin | Iovance Biotherapeutics | 59 | |
| Catherine MD | Syndax Pharmaceuticals | 52 | |
| Tracy Winton | Iovance Biotherapeutics | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
| Asif Ali | Protagonist Therapeutics | 50 | |
| Abha Bommireddi | Protagonist Therapeutics | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Carter King | Protagonist Therapeutics | 53 | |
| Adrian MD | Zentalis Pharmaceuticals Llc | N/A | |
| Andrea JD | Zentalis Pharmaceuticals Llc | 43 | |
| Michele PMP | Iovance Biotherapeutics | N/A | |
| Kevin Smyth | Iovance Biotherapeutics | N/A | |
| MBA MBA | Iovance Biotherapeutics | 67 | |
| FRAPS BSc | Puma Biotechnology | 59 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -2.93 | ||||
| Return On Asset | -0.98 |
Cardio Diagnostics Leadership Team
Elected by the shareholders, the Cardio Diagnostics' board of directors comprises two types of representatives: Cardio Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardio. The board's role is to monitor Cardio Diagnostics' management team and ensure that shareholders' interests are well served. Cardio Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardio Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Esq JD, Chief Officer | ||
| Timur Dogan, Chief Officer | ||
| Meeshanthini Dogan, CEO CoFounder | ||
| Khullani JD, Vice Strategy | ||
| MBA JD, CFO Director | ||
| Khullani Abdullah, VP Strategy |
Cardio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardio Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.93 | ||||
| Return On Asset | -0.98 | ||||
| Operating Margin | (162.96) % | ||||
| Number Of Shares Shorted | 13.02 K | ||||
| Revenue | 17.07 K | ||||
| EBITDA | (1.53 M) | ||||
| Net Income | (8.38 M) | ||||
| Total Debt | 1.26 M | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (5.67 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cardio Stock Analysis
When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.